Get the Stockscreener App
3.01
3.83%
-0.12
Century Therapeutics Inc stock is currently priced at $3.01, with a 24-hour trading volume of 73,782.
It has seen a -3.83% decreased in the last 24 hours and a +5.99% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $3.12 pivot point. If it approaches the $2.93 support level, significant changes may occur.
Previous Close:
$3.13
Open:
$3.15
24h Volume:
73,782
Market Cap:
$249.37M
Revenue:
$2.24M
Net Income/Loss:
$-136.67M
P/E Ratio:
-1.3871
EPS:
-2.17
Net Cash Flow:
$-102.08M
1W Performance:
-3.83%
1M Performance:
+5.99%
6M Performance:
+118.12%
1Y Performance:
-2.90%
1D Range:
$2.95
$3.1862
52W Range:
$1.28
$5.51
Century Therapeutics Inc Stock (IPSC) Company Profile
Name
Century Therapeutics Inc
Sector
Industry
Phone
267-817-5790
Address
3675 Market Street, Philadelphia
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-27-22 | Initiated | Chardan Capital Markets | Buy |
| Oct-31-22 | Initiated | Guggenheim | Buy |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| May-23-22 | Initiated | H.C. Wainwright | Buy |
| May-12-22 | Initiated | William Blair | Mkt Perform |
| Jul-13-21 | Initiated | BofA Securities | Buy |
| Jul-13-21 | Initiated | JP Morgan | Overweight |
| Jul-13-21 | Initiated | Piper Sandler | Overweight |
View All
Century Therapeutics Inc Stock (IPSC) Latest News
Century Therapeutics, Inc. (NASDAQ:IPSC) Sees Large Decline in Short Interest - MarketBeat
MarketBeat
Century Therapeutics Rallies On Bristol Myers Squibb Strategic Collaboration - Yahoo Singapore News
Yahoo Singapore News
After Plunging -29.84% in 4 Weeks, Here's Why the Trend Might Reverse for Century Therapeutics, Inc. (IPSC) - Yahoo New Zealand News
Yahoo New Zealand News
HC Wainwright Trims Century Therapeutics (NASDAQ:IPSC) Target Price to $11.00 - Defense World
Defense World
Century Therapeutics, Inc. Forecasted to Post Q1 2025 Earnings of ($0.48) Per Share (NASDAQ:IPSC) - MarketBeat
MarketBeat
Century Therapeutics Announces Expansion and Significant Progress in Autoimmune and Cancer Therapies - MSN
MSN
Century Therapeutics Inc Stock (IPSC) Financials Data
Century Therapeutics Inc (IPSC) Revenue 2024
IPSC reported a revenue (TTM) of $2.23 million for the quarter ending December 31, 2023, a -57.01% decline year-over-year.
Century Therapeutics Inc (IPSC) Net Income 2024
IPSC net income (TTM) was -$136.67 million for the quarter ending December 31, 2023, a -4.38% decrease year-over-year.
Century Therapeutics Inc (IPSC) Cash Flow 2024
IPSC recorded a free cash flow (TTM) of -$102.08 million for the quarter ending December 31, 2023, a -516.75% decrease year-over-year.
Century Therapeutics Inc (IPSC) Earnings per Share 2024
IPSC earnings per share (TTM) was -$2.29 for the quarter ending December 31, 2023, a -0.44% decline year-over-year.
Century Therapeutics Inc Stock (IPSC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Farid Adrienne | Chief Operations Officer |
May 03 '24 |
Sale |
3.11 |
913 |
2,836 |
137,236 |
| Carr Douglas | SVP Finance & Operations |
May 03 '24 |
Sale |
3.11 |
257 |
798 |
317,323 |
| Russotti Gregory | See Remarks |
Apr 22 '24 |
Sale |
3.10 |
5,000 |
15,490 |
297,319 |
| Farid Adrienne | Chief Operations Officer |
Mar 07 '24 |
Option Exercise |
1.03 |
22,831 |
23,516 |
136,980 |
| Farid Adrienne | Chief Operations Officer |
Mar 07 '24 |
Sale |
5.14 |
22,831 |
117,342 |
114,149 |
| Farid Adrienne | Chief Operations Officer |
Mar 06 '24 |
Option Exercise |
1.03 |
30,684 |
31,605 |
144,833 |
| Farid Adrienne | Chief Operations Officer |
Mar 06 '24 |
Sale |
4.96 |
30,684 |
152,340 |
114,149 |
| Farid Adrienne | Chief Operations Officer |
Feb 16 '24 |
Option Exercise |
1.03 |
485 |
500 |
114,634 |
| Farid Adrienne | Chief Operations Officer |
Feb 16 '24 |
Sale |
4.86 |
485 |
2,358 |
114,149 |
| Farid Adrienne | Chief Operations Officer |
Feb 06 '24 |
Sale |
4.49 |
1,784 |
8,005 |
114,149 |
About Century Therapeutics Inc
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT or CAR-iNK candidate targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia. The company was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
0.77%
1.20%
Cap:
|
Volume (24h):